UPDATE 1-Biopharmaceutical firm Eikon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> files for US IPOAdds details throughout
Jan 9 (Reuters) - Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.
Eikon Therapeutics is a late-stage clinical biopharmaceutical firm developing innovative medicines for serious unmet medical needs, with an initial focus on oncology.
It will list on the Nasdaq under the symbol "EIKN".
J.P. Morgan, Morgan Stanley and BofA Securities are the underwriters for the offering.
(Reporting by Prakhar Srivastava in Bengaluru; Editing by Alan Barona)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments